EUVIMEDEUVIMED entdecken
Crossref

Secondary Malignancies in Patients with Meningioma: A Surveillance, Epidemiology, and End Results (Seer) Data Analysis

Maxwell W. Pickles, Thomas Z. Rohan, David P. Bray, James J. Evans

Journal of Neurological Surgery Part B: Skull Base · 01.02.2024 · 85 (S 01 S 01) · S1-S398

DOI: 10.1055/s-0044-1780137 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neurological Surgery Part B: Skull Base, erschienen am 01.02.2024. Verfasst von Maxwell W. Pickles und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Meningiomas are commonly encountered intracranial masses. There is limited knowledge regarding the risk of developing other malignancies, the so-called “secondary malignancies” (SM) in a patient with a meningioma. We evaluated the risk of developing a SM after a meningioma diagnosis.

Methods

The Surveillance, Epidemiology, and End Results (SEER-17) data registry, which consisted of 9,208,295 patients was utilized to generate a cohort of 124,769 patients diagnosed with meningioma to identify patients at risk for a SM. The SEER patient data were collected from the years 2000 to 2020. Statistical analysis was performed through SEER’s statistical analysis package and standardized incidence ratios (SIRs) for various malignancies after the diagnosis of primary meningioma was obtained. We also collected basic demographic, surgical, and postoperative data.

Results

Of the 124,769 patients, 11,411 (9.2%) received diagnoses of a SM, which correlates to a higher risk than the general population (SIR: 1.17; 99% CI: 1.15–1.19). Patients with meningiomas had an increased risk of the following cancers: cutaneous melanoma (SIR, 1.40; 99% CI, 1.26–1.56), kidney and renal pelvis (SIR, 1.66; 99% CI, 1.47–1.86), brain and other nervous system (SIR, 3.45; 99% CI, 2.99–3.97), thyroid (SIR, 2.48; 99% CI, 2.19–2.80), and non-Hodgkin’s lymphoma (SIR, 1.29; 99% CI, 1.15–1.44). Females were more predisposed to cancers of the lung (SIR, 1.19; 99% CI: 1.12–1.26), digestive system (SIR, 1.06; 99% CI, 1.01–1.12), and breast (SIR, 1.09; 99% CI 1.04–1.14).

Conclusion

Employing the SEER database, we demonstrated that there is an increased risk in developing certain SM after diagnosis of meningioma. Further research may illuminate possible shared genetic abnormalities between the development of meningioma and these SMs. The overall rate of SM in patients with meningioma, however, is not likely high enough to warrant additional screening recommendations ([ Fig. 1 ]; [ Tables 1 ] and [ 2 ]). Fig. 1 Table 1 Table 2 Publication History Article published online: 05 February 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Pickles, M. W., Rohan, T. Z., Bray, D. P., & Evans, J. J. (2024). Secondary Malignancies in Patients with Meningioma: A Surveillance, Epidemiology, and End Results (Seer) Data Analysis. Journal of Neurological Surgery Part B: Skull Base, 85(S 01 S 01), S1-S398. https://doi.org/10.1055/s-0044-1780137

Vancouver

Pickles MW, Rohan TZ, Bray DP, Evans JJ. Secondary Malignancies in Patients with Meningioma: A Surveillance, Epidemiology, and End Results (Seer) Data Analysis. Journal of Neurological Surgery Part B: Skull Base. 2024;85(S 01 S 01):S1-S398. doi:10.1055/s-0044-1780137

BibTeX
@article{Pickles2024,
  author = {Pickles, Maxwell W. and Rohan, Thomas Z. and Bray, David P. and Evans, James J.},
  title = {Secondary Malignancies in Patients with Meningioma: A Surveillance, Epidemiology, and End Results (Seer) Data Analysis},
  journal = {Journal of Neurological Surgery Part B: Skull Base},
  year = {2024},
  volume = {85},
  number = {S 01 S 01},
  pages = {S1--S398},
  doi = {10.1055/s-0044-1780137}
}
Kostenlos starten →